Anaplastic thyroid carcinoma

Pathogenesis and emerging therapies

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally. Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes contribute to its aggressive behaviour, and recent studies (e.g. microarrays, microRNAs) have provided further insights into its complex molecular dysregulation. Preclinical studies have identified numerous proteins over- or underexpressed that affect critical cellular processes, including transcription, signalling, mitosis, proliferation, cell cycle, apoptosis and adhesion, and a variety of agents that effectively inhibit these processes and tumour growth. In clinical studies of 1771 patients, 64% were women, the median survival was 5 months, and 1-year survival was 20%. The variables associated with survival in some series included age, tumour size, extent of surgery, higher dose radiotherapy, absence of distant metastases at presentation, co-existence of differentiated thyroid cancer and multimodality therapy. However, considerable bias exists in these non-randomised studies. Although more aggressive radiotherapy has reduced locoregional recurrences, the median overall survival has not improved in over 50 years. Newer systemic therapies are being tried, and more effective combinations are needed to improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)486-497
Number of pages12
JournalClinical Oncology
Volume22
Issue number6
DOIs
StatePublished - Aug 2010

Fingerprint

Survival
Thyroid Neoplasms
Radiotherapy
Therapeutics
Tumor Suppressor Genes
MicroRNAs
Oncogenes
Mitosis
Cell Adhesion
Neoplasms
Cell Cycle
Apoptosis
Neoplasm Metastasis
Recurrence
Mutation
Anaplastic Thyroid Carcinoma
Growth
Proteins
Clinical Studies

Keywords

  • Anaplastic
  • Chemotherapy
  • Microarray
  • Mutations
  • Radiotherapy
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Anaplastic thyroid carcinoma : Pathogenesis and emerging therapies. / Smallridge, Robert Christian; Copland, John A III.

In: Clinical Oncology, Vol. 22, No. 6, 08.2010, p. 486-497.

Research output: Contribution to journalArticle

@article{4bf1460c0cd04578acd2b634260f35df,
title = "Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies",
abstract = "Anaplastic thyroid carcinoma ranges from 1.3 to 9.8{\%} of all thyroid cancers globally. Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes contribute to its aggressive behaviour, and recent studies (e.g. microarrays, microRNAs) have provided further insights into its complex molecular dysregulation. Preclinical studies have identified numerous proteins over- or underexpressed that affect critical cellular processes, including transcription, signalling, mitosis, proliferation, cell cycle, apoptosis and adhesion, and a variety of agents that effectively inhibit these processes and tumour growth. In clinical studies of 1771 patients, 64{\%} were women, the median survival was 5 months, and 1-year survival was 20{\%}. The variables associated with survival in some series included age, tumour size, extent of surgery, higher dose radiotherapy, absence of distant metastases at presentation, co-existence of differentiated thyroid cancer and multimodality therapy. However, considerable bias exists in these non-randomised studies. Although more aggressive radiotherapy has reduced locoregional recurrences, the median overall survival has not improved in over 50 years. Newer systemic therapies are being tried, and more effective combinations are needed to improve patient outcomes.",
keywords = "Anaplastic, Chemotherapy, Microarray, Mutations, Radiotherapy, Surgery",
author = "Smallridge, {Robert Christian} and Copland, {John A III}",
year = "2010",
month = "8",
doi = "10.1016/j.clon.2010.03.013",
language = "English (US)",
volume = "22",
pages = "486--497",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Anaplastic thyroid carcinoma

T2 - Pathogenesis and emerging therapies

AU - Smallridge, Robert Christian

AU - Copland, John A III

PY - 2010/8

Y1 - 2010/8

N2 - Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally. Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes contribute to its aggressive behaviour, and recent studies (e.g. microarrays, microRNAs) have provided further insights into its complex molecular dysregulation. Preclinical studies have identified numerous proteins over- or underexpressed that affect critical cellular processes, including transcription, signalling, mitosis, proliferation, cell cycle, apoptosis and adhesion, and a variety of agents that effectively inhibit these processes and tumour growth. In clinical studies of 1771 patients, 64% were women, the median survival was 5 months, and 1-year survival was 20%. The variables associated with survival in some series included age, tumour size, extent of surgery, higher dose radiotherapy, absence of distant metastases at presentation, co-existence of differentiated thyroid cancer and multimodality therapy. However, considerable bias exists in these non-randomised studies. Although more aggressive radiotherapy has reduced locoregional recurrences, the median overall survival has not improved in over 50 years. Newer systemic therapies are being tried, and more effective combinations are needed to improve patient outcomes.

AB - Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally. Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes contribute to its aggressive behaviour, and recent studies (e.g. microarrays, microRNAs) have provided further insights into its complex molecular dysregulation. Preclinical studies have identified numerous proteins over- or underexpressed that affect critical cellular processes, including transcription, signalling, mitosis, proliferation, cell cycle, apoptosis and adhesion, and a variety of agents that effectively inhibit these processes and tumour growth. In clinical studies of 1771 patients, 64% were women, the median survival was 5 months, and 1-year survival was 20%. The variables associated with survival in some series included age, tumour size, extent of surgery, higher dose radiotherapy, absence of distant metastases at presentation, co-existence of differentiated thyroid cancer and multimodality therapy. However, considerable bias exists in these non-randomised studies. Although more aggressive radiotherapy has reduced locoregional recurrences, the median overall survival has not improved in over 50 years. Newer systemic therapies are being tried, and more effective combinations are needed to improve patient outcomes.

KW - Anaplastic

KW - Chemotherapy

KW - Microarray

KW - Mutations

KW - Radiotherapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=77954760114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954760114&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2010.03.013

DO - 10.1016/j.clon.2010.03.013

M3 - Article

VL - 22

SP - 486

EP - 497

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 6

ER -